Is ibogaine legal now?

A colleague asked me last month if the recent Executive Order made ibogaine legal. It didn’t. Ibogaine is still Schedule I, and the order doesn’t change that.

It’s still worth talking about ibogaine. Media coverage has been mostly promise or panic, and neither is the clinical picture our clients deserve. The anti-addiction signal is real. A single treatment can suppress opioid withdrawal and craving in a way no other compound can. The evidence is also thin. The strongest recent human data come from 30 veterans, no control group, self-pay, short follow-up.

The cardiac risk is real too. Ibogaine blocks the heart’s hERG channel at ordinary therapeutic doses, which can prolong the QT interval and trigger a fatal arrhythmia in people with no prior cardiac disease. In the largest safety analysis to date (a preprint following over 19,000 patients), every death clustered in one group: people being treated for opioid use disorder, most of them in unsupervised detox, often abroad.

Federally prohibiting ibogaine did not remove risk. It pushed the highest-risk use into the least-monitored settings: opioid detox by people who are often desperate and out of options. That is a reason to be honest about what drives people toward such risks.

If a client wants to discuss ibogaine, do not endorse or dismiss it. Have an accurate picture and a few questions ready before the conversation goes further.

I wrote up the mechanism, the mortality data, and where safer analogs stand: ibogaine’s anti-addiction signal against its cardiac risk.

Peter

P.S. For the conversation after a client tells you they have already used something outside your office, the free guide is here: What to Do After Your Client Uses Psychedelics.